Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 0 | 0 | 20,000 | 0 | 100 |
| Gross Profit | N/A | N/A | 20,000 | N/A | 100 |
| Operating Expenses | 30,728 | 24,126 | 24,866 | 20,197 | 15,641 |
| Operating Income | -30,728 | -24,126 | -4,866 | -20,197 | -15,541 |
| Interest Expense | 0 | 1 | 1 | 1 | 1 |
| Other Income | 3,462 | -59 | -74 | -137 | -80 |
| Pre-tax Income | -27,266 | -24,186 | -4,941 | -20,335 | -15,622 |
| Income Tax | N/A | N/A | 1,999 | -38 | N/A |
| Net Income Continuous | -27,266 | -24,186 | -6,940 | -20,297 | -15,622 |
| Net Income | $-27,266 | $-24,186 | $-6,940 | $-20,297 | $-15,622 |
| EPS Basic Total Ops | -1.13 | -1.01 | -0.30 | -0.87 | -0.67 |
| EPS Basic Continuous Ops | -1.13 | -1.01 | -0.29 | -0.87 | -0.67 |
| EPS Diluted Total Ops | -1.13 | -1.01 | -0.30 | -0.87 | -0.67 |
| EPS Diluted Continuous Ops | -1.13 | -1.01 | -0.29 | -0.87 | -0.67 |
| EBITDA(a) | $-30,420 | $-24,013 | $-4,762 | $-20,094 | $-15,450 |